Catégorie : Cannabis et Réduction des Risques

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, janvier 2022

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]

Lire la suite

Early Consumption of Cannabinoids : From Adult Neurogenesis to Behavior, Citlalli Netzahualcoyotzi et al., 2021

Early Consumption of Cannabinoids : From Adult Neurogenesis to Behavior Citlalli Netzahualcoyotzi, Luis Miguel Rodríguez-Serrano, María Elena Chávez-Hernández and Mario Humberto Buenrostro-Jáuregui International Journal of Molecular Sciences, 2021, 22, 7450. doi : 10.3390/ijms22147450   Abstract The endocannabinoid system (ECS) is a crucial modulatory system in which interest has been increasing, particularly regarding the regulation of behavior and neuroplasticity. The adolescent–young adulthood phase of development comprises a critical period in the maturation of the nervous system and the ECS. Neurogenesis occurs in discrete regions of the adult brain, and this process is linked to the modulation of some behaviors. Since marijuana (cannabis) is the most consumed illegal [...]

Lire la suite

Cannabidiol as a treatment for craving and relapse inindividuals with cocaine use disorder: a randomizedplacebo-controlled trial, Violaine Mongeau-Pérusse, et al., 2021

Cannabidiol as a treatment for craving and relapse inindividuals with cocaine use disorder: a randomized placebo-controlled trial Violaine Mongeau-Pérusse, Suzanne Brissette, Julie Bruneau, Patricia Conrod, Simon Dubreucq, Guillaume Gazil, EmmanuelStip & DidierJutras-Aswad Addiction, 2021, 116, (9), 1-12. Doi : 10.1111/add.15417   ABSTRACT Background and Aims : Cocaine use disorder (CUD) is a significant public health concern for which no efficacious phar-macologicalinterventionsare available. Cannabidiol (CBD) has attracted considerable interest as a promisingtreatmentforaddiction. This study tested CBD efficacy for reducing craving and preventing relapse in people with CUD.DesignSingle-site double-blind randomized controlled superiority trial comparing CBD with placebo. Setting and Participants : Centre Hospitalier de l’Université de Montréal, Canada. Seventy-eight [...]

Lire la suite

Cannabinoids, Pain, and Opioid Use Reduction : The Importance of Distilling and Disseminating Existing Data, Kent E. Hutchison et al., 2019

Cannabinoids, Pain, and Opioid Use Reduction : The Importance of Distilling and Disseminating Existing Data Kent E. HUTCHISON, Sarah L. HAGERTY, Jeffrey GALINKIN, Angela D. BRYAN, L. Cinnamon BIDWELL Cannabis and Cannabinoid Research, 2019, 4, (3), 158-164. Doi : 10.1089/can.2018.0052   Abstract The high prevalence of chronic pain conditions combined with an over-reliance on opioid prescriptions has resulted in an opioid epidemic and a desperate need for solutions. There is some debate about whether cannabis might play a role in addressing chronic pain conditions as well as the opioid epidemic. Recent surveys suggest that a large number of people are using cannabis as a treatment for [...]

Lire la suite

Pharmacologie du Cannabidiol : Points de vigilance, conséquences et risques chez l’homme, Association Française des centres d’Addictovigilance : Pr Joëlle MICALLEF, Dr Anne BATISSE, Dr Bruno REVOL, décembre 2021

Pharmacologie du Cannabidiol : Points de vigilance, conséquences et risques chez l’homme Note rédigée par l’Association Française des centres d’Addictovigilance : Pr Joëlle MICALLEF, Dr Anne BATISSE, Dr Bruno REVOL, décembre 2021   Contexte Le Cannabidiol (CBD) est l’un des principaux phytocannabinoïdes présent dans Cannabis sativa, avec le THC. A ce jour, un seul produit contenant uniquement du CBD (nom de ce médicament Epidyolex®) est disponible sur le marché français, son Autorisation de Mise sur le Marché (AMM) lui conférant une indication médicale en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au syndrome de Dravet, chez les [...]

Lire la suite

L’INDISPENSABLE SUR… LE CANNABIDIOL (CBD), MILDECA, 2021

L’INDISPENSABLE SUR... LE CANNABIDIOL (CBD) MILDECA Mission interministérielle de lutte contre les drogues et les conduites addictives 2021   Qu’est-ce que le cannabidiol ? C’est : 􀂝 une des principales substances actives de type cannabinoïde de la plante de chanvre, au même titre que le THC (delta-9-tétrahydrocannabinol). On la trouve principalement au niveau de la fleur et des feuilles adjacentes. 􀂝 un composant, sous forme d’extrait, de médicaments ou de produits de consommation courante, dont seuls certains sont autorisés en France. Ce n’est pas : 􀂝 un stupéfiant. Le CBD reste tout de même une substance à effet psychoactif, qui peut avoir des interactions avec d'autres molécules, notamment des médicaments. 􀂝 une [...]

Lire la suite

Medical cannabis authorization and the risk of cardiovascular events : a longitudinal cohort study, Arsene Zongo et al.,

Medical cannabis authorization and the risk of cardiovascular events : a longitudinal cohort study Arsene Zongo, Cerina Lee, Jason R. B. Dyck, Jihane El‑Mourad, Elaine Hyshka, John G. Hanlon and Dean T. Eurich BMC Cardiovascular Disorders, 2021, 21, 426 doi : 10.1186/s12872-021-02229-6   Abstract Background : Cannabis is increasingly used for therapeutic purpose. However, its safety profile is not well known. This study assessed the risk of cardiovascular-related emergency department (ED) visit and hospitalization in adult patients authorized to use medical cannabis in Ontario, Canada from 2014 to 2017. Methods : This is a longitudinal cohort study of patients who received medical cannabis authorization and followedup in [...]

Lire la suite

Scoping Review and Meta-Analysis Suggests that Cannabis Use May Reduce Cancer Risk in the United State, Thomas M. Clark, 2021

Scoping Review and Meta-Analysis Suggests that Cannabis Use May Reduce Cancer Risk in the United States Thomas M. Clark Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 413-434. Doi : 10.1089/can.2019.0095   Abstract Introduction:Cannabis smoke contains carcinogens similar to tobacco, in addition to compounds with antitumor activity. Cannabis use reduces the risk of obesity and cannabinoids inhibit chronic inflammation, known causes of cancer. The net effect of Cannabis use on cancer risk is not known. Objective: To examine the association between Cannabis use and cancer risk in the United States. Methods: Identify and analyze published data on cancer risk in Cannabis users. Results: A total of 55 data [...]

Lire la suite

Cannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression, Carmen A. Zavala et al., 2021

Cannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression Carmen A. Zavala, Ana C. Thomaz, Vishakh Iyer, Ken Mackie, and Andrea G. Hohmann Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 389-400. DOI: 10.1089/can.2020.0059   Abstract Introduction : Overdose fatalities associated with the opioid epidemic are predictably attributable to druginduced respiratory depression. In terms of illicit opioid abuse, fentanyl is the synthetic opioid responsible for the largest number of overdose deaths. There is, therefore, an urgent need to identify safe and effective therapeutics that can attenuate fentanyl-induced respiratory depression. Identification of effective alternate analgesic strategies that lessen the respiratory depression associated with narcotics would also help [...]

Lire la suite

Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression, Beth M. Wiese et al., 2021

Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression Beth M. Wiese, Erika Liktor-Busa, Aidan Levine, Sarah A. Couture, Spyros P. Nikas, Lipin Ji, Yingpeng Liu, Kenneth Mackie, Alexandros Makriyannis, Tally M. Largent-Milnes and Todd W. Vanderah Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 401-412. Doi : 10.1089/can.2020.0076   Abstract Introduction : An escalating number of fatalities resulting from accidental opioid overdoses typically attributed to respiratory depression continue to define the opioid epidemic. Opioid respiratory depression results from a decrease in reflexive inspiration within the preBo¨ tzinger complex in the brainstem. Objective : Cannabinoid receptor agonism is reported to enhance opioid analgesia, yet whether cannabinoids enhance [...]

Lire la suite